Skip to main content
Log in

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

New slow-release buprenorphine formulations for optimization of opioid substitution

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Die Opioidsubstitution mit Methadon oder Buprenorphin ist eine anerkannte, weltweit praktizierte First-line-Behandlung der Opioidabhängigkeit. Neben dem in Deutschland bereits verfügbaren wöchentlich oder monatlich subkutan injizierbaren Buprenorphin Depot CAM 2038 (Buvidal®) stehen mit dem monatlich zu applizierenden Depotpräparat RBP-6000 (Sublocade™) und dem 6 Monate wirkenden Buprenorphin-Depot-Implantat (Probuphine™) demnächst wahrscheinlich mehrere langzeitwirksame Buprenorphinformulierungen zur Verfügung. Der bisherige Wissensstand und mögliche Einsatzgebiete dieser Präparate werden diskutiert.

Abstract

Opioid maintenance treatment with methadone or buprenorphine is an established first-line treatment for opioid dependence. In addition to the novel weekly and monthly subcutaneously injectable buprenorphine depot CAM 2038 (Buvidal®), which is already available in Germany, two other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade™) and a 6-month buprenorphine depot implant (Probuphine™). Basic pharmacological and clinical data of these three medications are given and possible clinical applications are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F (2017) Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 34:560–575

    Article  CAS  PubMed  Google Scholar 

  2. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S (2008) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 4:CD5031

    Google Scholar 

  3. Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 9:CD5031

    Google Scholar 

  4. Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 10:CD4147

    Google Scholar 

  5. Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A (2017) Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 7:119–134. https://doi.org/10.1177/2045125316681984

    Article  CAS  PubMed  Google Scholar 

  6. Bundesärztekammer (2017) Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opioidabhängiger. www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/RL/Substitution.pdf. Zugegriffen: 28. Mai 2019

    Google Scholar 

  7. Center for Behavioral Health Statistics and Quality (CBHSQ) (2016) National survey on drug use and health: detailed tables. Substance abuse and mental health services administrations. SAMHSA, Rockville

    Google Scholar 

  8. Deamer RL, Wilson DR, Clark DS, Prichard JG (2001) Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 20:7–14. https://doi.org/10.1300/J069v20n04_02

    Article  CAS  PubMed  Google Scholar 

  9. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N et al (2014) The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 109(8):1320–1333

    Article  PubMed  Google Scholar 

  10. Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D (2016) A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of Opioid addiction. J Addict Med 10(2):93–103

    Article  CAS  PubMed  Google Scholar 

  11. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW (2008) A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165(2):179–187

    Article  PubMed  Google Scholar 

  12. European Agency for the Evaluation of Medical Products (2001). EMEA public statement to suspend the marketing authorisation for Orlaam (levoacetylmethadol) in the European Union. EMEA/8776/01.

  13. Fareed A, Vayalapalli S, Casarella J, Drexler K (2012) Effect of buprenorphine dose on treatment outcome. J Addict Dis 31:8–18

    Article  PubMed  Google Scholar 

  14. US Food and Drug Administration (2016) Probuphine™ prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204442Orig1s000lbl.pdf

    Google Scholar 

  15. Greenwald MK, Comer SD, Fiellin DA (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 144:1–11

    Article  CAS  PubMed  Google Scholar 

  16. Greenwald MK, Johanson CE, Moody DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000–2009

    Article  CAS  PubMed  Google Scholar 

  17. Haasen C, Linden M, Tiberg F (2017) Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J Subst Abuse Treat 78:22–29

    Article  PubMed  Google Scholar 

  18. Haight BR, Learned SM, Laffont CM, Fudala J, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbrder C, RB-US-13-0001 Study Investigators (2019) Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 393(10173):778–790. https://doi.org/10.1016/S0140-6736(18)32259-1

    Article  CAS  PubMed  Google Scholar 

  19. Hser YI, Evans E, Huang D et al (2016) Long-term outcomes after randomization to buprenorphiine/naloxone versus methadone in a multi-site trial. Addiction 111:695–705

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hser YI, Huang D, Saxon AJ et al (2017) Distinctine trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+naloxone and methadone. J Addict Med 11:63–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hser YI, Saxon AJ, Huang D et al (2014) Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 109:8–18

    Google Scholar 

  22. Itzoe M, Guarnieri M (2017) New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des Devel Ther 11:1429–1437. https://doi.org/10.2147/DDDT.S109331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750–2755

    Article  CAS  PubMed  Google Scholar 

  24. Kenney SR, Anderson BJ, Bailey GL, Stein MD (2018) Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management. J Subst Abuse Treat 94:55–59. https://doi.org/10.1016/j.jsat.2018.08.011

    Article  PubMed  Google Scholar 

  25. Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF (2016) Population Pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously Injectable, long-acting, sustained-release formulation of Buprenorphine, for the treatment of Opioid use disorder. J Clin Pharmacol 56:806–815

    Article  CAS  PubMed  Google Scholar 

  26. Ling W, Charuvastra C, Collins JF et al (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475

    Article  CAS  PubMed  Google Scholar 

  27. Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C (2019) Patient-centered outcomes in participants of a Buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, Multicenter, phase 3 study. J Addict Med. https://doi.org/10.1097/ADM.0000000000000517

    Article  PubMed  Google Scholar 

  28. Lofwall MR, Walsh SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experience from around the world. J Addict Med 8:315–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S (2018) Weekly and monthly subcutaneous Buprenorhpine depot formulations vs daily Sublingual Burpenorphine with Naloxone for treatment of Opioid use disorder: a randomized clinical trial. JAMA Intern Med 178:764–773

    Article  PubMed  PubMed Central  Google Scholar 

  30. Mattick RP, Breen C, Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207. https://doi.org/10.1002/14651858.CD002207.pub4

    Article  PubMed  Google Scholar 

  31. Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK (2014) A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 53:813–824

    Article  PubMed  Google Scholar 

  32. Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP 3rd, Heidbreder C (2016) Sustained-release Buprenorphine (RBP-6000) blocks the effects of Opioid challenge with Hydromorphone in subjects with Opioid use disorder. J Clin Psychopharmacol 36:18–26. https://doi.org/10.1097/JCP

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, Walter M, Seifritz E, Dürsteler KM, Herdener M (2019) One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction 114:103–111. https://doi.org/10.1111/add.14442

    Article  PubMed  Google Scholar 

  34. Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, PRO-814 Study Group (2016) Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical traial. JAMA 316:282–290

    Article  CAS  PubMed  Google Scholar 

  35. Rosenthal RN, Ling W, Casadonte P et al (2013) Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 108:2141–2149

    Article  PubMed  PubMed Central  Google Scholar 

  36. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR (1997) Buprenorphine vs methadone maintenance treatment for concurrent opiod dependence and cocaine abuse. Arch Gen Psychiatry 54:713–720

    Article  CAS  PubMed  Google Scholar 

  37. Schuckit MA (2016) Treatment of opioid-use disorders. N Engl J Med 375:1596–1597

    Article  PubMed  Google Scholar 

  38. Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA (2019) Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1406

    Article  PubMed  PubMed Central  Google Scholar 

  39. Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H‑U (2017) Six-year outcome of Opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res 23(2):97–105

    Article  PubMed  Google Scholar 

  40. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C (2016) Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis 35(1):22–35

    Article  PubMed  Google Scholar 

  41. Volkow ND, Frieden TR, Hyde PS, Cha SS (2014) Medication-Assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med 370:2063–2066

    Article  PubMed  Google Scholar 

  42. Walsh SL, Comer SD, Lofwall MR et al (2017) Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry 74:894–902. https://doi.org/10.1001/jamapsychiatry.2017.1874

    Article  PubMed  PubMed Central  Google Scholar 

  43. Walter M, Soyka M (2019) Opioide. In: Soyka M et al (Hrsg) Suchtmedizin. Elsevier, München, S 177–202

    Chapter  Google Scholar 

  44. White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL (2009) Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 103:37–43. https://doi.org/10.1016/j.drugalcdep.2009.03.008

    Article  CAS  PubMed  Google Scholar 

  45. Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, Scherbaum N (2009) Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation—results from a controlled clinical trial. Eur J Med Res 14:7–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, Scherbaum N (2009) A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 42:1–8. https://doi.org/10.1055/s-0028-1083818

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Soyka.

Ethics declarations

Interessenkonflikt

M. Soyka und O. Pogarell geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soyka, M., Pogarell, O. Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution. Nervenarzt 90, 932–937 (2019). https://doi.org/10.1007/s00115-019-0783-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-019-0783-6

Schlüsselwörter

Keywords

Navigation